Due to the correlation between PD-L1 expression and response to anti-PD-1 treatment [15], most clinical trials are currently focusing on treating cancers known to express high levels of PD-L1 such as melanoma and non-small cell lung cancer [16]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.